These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2667310)

  • 1. Acute responses to urapidil in hypertensive persons.
    de Leeuw PW; Birkenhäger WH
    Am J Cardiol; 1989 Aug; 64(7):22D-24D. PubMed ID: 2667310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal haemodynamic and neurohumoral responses to urapidil in hypertensive man.
    de Leeuw PW; van Es PN; de Bruyn HA; Birkenhäger WH
    Drugs; 1988; 35 Suppl 6():74-7. PubMed ID: 2900132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the calcium antagonist felodipine on the sympathetic and renin-angiotensin-aldosterone systems in essential hypertension.
    Katzman PL; Hulthén UL; Hökfelt B
    Acta Med Scand; 1988; 223(2):125-31. PubMed ID: 3279724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular and metabolic profile during intervention with urapidil in humans.
    Gerber A; Weidmann P; Marone C; Uehlinger D; Riesen W
    Hypertension; 1985; 7(6 Pt 1):963-71. PubMed ID: 3908316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal haemodynamics and sodium excretory capacity during urapidil treatment in patients with essential hypertension.
    Lavrijssen AT; Kroon AA; Fuss-Lejeune M; Schiffers PM; de Leeuw PW
    J Hypertens; 2000 Jul; 18(7):963-9. PubMed ID: 10930195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Renal and adrenal function following acute administration of urapidil in hypertensive patients with normal and impaired renal function].
    Wambach G; Godehardt E; Lang R; Haerlin R; Meurer KA
    Arzneimittelforschung; 1987 Aug; 37(8):960-4. PubMed ID: 3675693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic and renal hemodynamic effects of celiprolol in essential hypertensives.
    Lucarini AR; Salvetti A
    Am J Cardiol; 1988 Feb; 61(5):45C-48C. PubMed ID: 2963525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of urapidil and atenolol in hypertension.
    Török E; Wagner M; Podmaniczky M
    Drugs; 1988; 35 Suppl 6():164-72. PubMed ID: 3042356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic assessment of urapidil or angiotensin-converting enzyme inhibition in systemic hypertension.
    Rosenthal J; Haerlin R
    Am J Cardiol; 1989 Aug; 64(7):25D-29D. PubMed ID: 2667311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Course of blood pressure within the first 12 h of hypertensive urgencies.
    Hirschl MM; Herkner H; Bur A; Woisetschläger C; Gamper G; Frossard M; Laggner AN
    J Hypertens; 1998 Feb; 16(2):251-5. PubMed ID: 9535154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive effects of urapidil and clonidine: a double-blind cross-over study.
    Kanniainen E; Heikkilä O; Jääskeläinen T; Lilja M; Jounela AJ
    Eur J Clin Pharmacol; 1985; 28(1):35-9. PubMed ID: 3886400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antihypertensive effect of urapidil in mild to moderate arterial hypertension. Randomized, double-blind versus placebo study].
    Amodeo C; Barros LM; Batlouni M; Sousa JE
    Arq Bras Cardiol; 1993 Aug; 61(2):127-30. PubMed ID: 8297222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic haemodynamic and humoral changes during urapidil treatment in hypertensive patients.
    Leonetti G; Terzoli L; Zanchetti A
    J Hypertens Suppl; 1988 Dec; 6(2):S25-9. PubMed ID: 2906697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neural control of circulation before and after intravenous urapidil in essential hypertension.
    Grassi G; Parati G; Pomidossi G; Giannattasio G; Casadei R; Groppelli A; Zanchetti A; Mancia G
    Drugs; 1988; 35 Suppl 6():104-10. PubMed ID: 3402353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate hemodynamic effects of urapidil in patients with essential hypertension.
    Kobrin I; Amodeo C; Ventura HO; Messerli FH; Frohlich ED
    Am J Cardiol; 1985 Mar; 55(6):722-5. PubMed ID: 3976516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of clinical trials with urapidil.
    Schook CE; Radtke H; Wurst W; Thieme G
    Am J Cardiol; 1989 Aug; 64(7):30D-37D. PubMed ID: 2667312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the antihypertensive effect of urapidil and metoprolol in hypertension.
    Leonetti G; Mazzola C; Boni S; Guffanti E; Meani A; Zanchetti A
    Eur J Clin Pharmacol; 1986; 30(6):637-40. PubMed ID: 3533561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of once-daily urapidil treatment in mild or moderate essential hypertension assessed by ambulatory 24-hour blood pressure monitoring.
    Trimarco B; Rosiello G; Feldhaus P; Steinijans VW; Vecchione F; Cuocolo A; Lembo G; Volpe M
    Drugs; 1988; 35 Suppl 6():173-81. PubMed ID: 3402355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Intravenous Urapidil for Older Hypertensive Patients with Acute Heart Failure: A Multicenter Randomized Controlled Trial.
    Yang W; Zhou YJ; Fu Y; Qin J; Qin S; Chen XM; Guo JC; Wang Z; Zhan H; Li J; He JY; Hua Q
    Yonsei Med J; 2017 Jan; 58(1):105-113. PubMed ID: 27873502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candesartan cilexetil and renal hemodynamics in hypertensive patients.
    Fridman K; Wysocki M; Friberg P; Andersson OK
    Am J Hypertens; 2000 Sep; 13(9):1045-8. PubMed ID: 10981559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.